Putting the award page together from the records…
Putting the award page together from the records…
COVID-19. TO DEVELOP SMALL SYNTHETIC CHEMICAL MOLECULES AS BROADLY ACTIVE ANTIVIRAL FOR THE TREATMENT OF VIRAL INFECTIONS.
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
32 subawards totaling $7.57M (122.0% of what was obligated), as The Leland Stanford Junior University reported them. Primes report subawards of $30,000 or more; smaller ones and unreported ones aren't here.
| Subcontractor | Amount | Subawards | Where | First | Last |
|---|---|---|---|---|---|
| Inotiv, Inc | $4.58M | 15 | IN | 2025-03-11 | 2026-07-24 |
| Uic Parent Corporation | $2.16M | 11 | NY | 2023-03-10 | 2026-06-29 |
| Fiore Principi Attivi SRL | $639.2K | 4 | CA | 2023-03-27 | 2025-07-01 |
| Aravasc, Inc | $188.9K | 2 | CA | 2025-09-10 | 2026-06-03 |
| Date | To | Amount | For |
|---|---|---|---|
| 2025-04-10 | Inotiv, Inc | $3.01M | TO DEVELOP SMALL SYNTHETIC CHEMICAL MOLECULES AS BROADLY ACTIVE ANTIVIRAL FOR THE TREATMENT OF VIRAL INFECTIONS) ADVANCING A LEAD BROAD SPECTRUM ANTIVIRAL PI-KINASE INHIBITOR |
| 2025-07-15 | Curia Global Inc | $844.6K | "CURIA DESCRIPTION OF WORK NON-GMP MANUFACTURE OF APPROXIMATELY3 KILOGRAM OF STF-2586 AND REPROCESSING AND RETESTING OF STF- 2586 TASK 19: NON-GMP BATCH SUBTASK 19A: BATCH PROCEDURE/RECORD REVIEW AND APPROVAL SUBTASK… |
| 2026-02-04 | Inotiv, Inc | $432.7K | TO DEVELOP SMALL SYNTHETIC CHEMICAL MOLECULES AS BROADLY ACTIVE ANTIVIRAL FOR THE TREATMENT OF VIRAL INFECTIONS) ADVANCING A LEAD BROAD SPECTRUM ANTIVIRAL PI-KINASE INHIBITOR |
| 2025-06-09 | Inotiv, Inc | $380.1K | TO DEVELOP SMALL SYNTHETIC CHEMICAL MOLECULES AS BROADLY ACTIVE ANTIVIRAL FOR THE TREATMENT OF VIRAL INFECTIONS) ADVANCING A LEAD BROAD SPECTRUM ANTIVIRAL PI-KINASE INHIBITOR |
17 actions since 2022-12-05. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2026-09-21 | P00022 | Option exercised | $5.20M | EO14398 TO DEVELOP SMALL SYNTHETIC CHEMICAL MOLECULES AS BROADLY ACTIVE ANTIVIRAL FOR THE TREATMENT OF VIRAL INFECTIONS |
| 2026-09-18 | P00021 | Administrative change | $0 | EO14398 TO DEVELOP SMALL SYNTHETIC CHEMICAL MOLECULES AS BROADLY ACTIVE ANTIVIRAL FOR THE TREATMENT OF VIRAL INFECTIONS |
| 2026-09-08 | P00020 | Funding only | -$3.31M | EO14398 TO DEVELOP SMALL SYNTHETIC CHEMICAL MOLECULES AS BROADLY ACTIVE ANTIVIRAL FOR THE TREATMENT OF VIRAL INFECTIONS |
| 2026-07-01 | P00019 | Administrative change | $0 | EO14398 TO DEVELOP SMALL SYNTHETIC CHEMICAL MOLECULES AS BROADLY ACTIVE ANTIVIRAL FOR THE TREATMENT OF VIRAL INFECTIONS |
| 2026-05-28 | P00018 | Administrative change | $0 | TO DEVELOP SMALL SYNTHETIC CHEMICAL MOLECULES AS BROADLY ACTIVE ANTIVIRAL FOR THE TREATMENT OF VIRAL INFECTIONS |
| 2026-05-05 | P00017 | Option exercised | $1.89M | TO DEVELOP SMALL SYNTHETIC CHEMICAL MOLECULES AS BROADLY ACTIVE ANTIVIRAL FOR THE TREATMENT OF VIRAL INFECTIONS |
| 2026-01-07 | P00016 | Administrative change | $0 | TO DEVELOP SMALL SYNTHETIC CHEMICAL MOLECULES AS BROADLY ACTIVE ANTIVIRAL FOR THE TREATMENT OF VIRAL INFECTIONS |
| 2025-09-25 | P00015 | Option exercised | $2.80M | TO DEVELOP SMALL SYNTHETIC CHEMICAL MOLECULES AS BROADLY ACTIVE ANTIVIRAL FOR THE TREATMENT OF VIRAL INFECTIONS |
| 2025-09-04 | P00014 | Funding only | -$376.8K | TO DEVELOP SMALL SYNTHETIC CHEMICAL MOLECULES AS BROADLY ACTIVE ANTIVIRAL FOR THE TREATMENT OF VIRAL INFECTIONS |
| 2025-05-21 | P00013 | Administrative change |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-09-30). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗
| 2025-05-14 |
| Curia Global Inc |
| $337.6K |
| "CURIA DESCRIPTION OF WORK NON-GMP MANUFACTURE OF APPROXIMATELY3 KILOGRAM OF STF-2586 AND REPROCESSING AND RETESTING OF STF- 2586 TASK 19: NON-GMP BATCH SUBTASK 19A: BATCH PROCEDURE/RECORD REVIEW AND APPROVAL SUBTASK… |
| 2025-07-01 | Acme Bioscience, Inc. | $245.2K | THE MEDICINAL CHEMISTRY FOCUS ON PI4K IS TO IDENTIFY A NOVEL SERIES OF BACK-UP COMPOUNDS THAT ARE DIVERSE WITH OFF-TARGET TOXICITY AS WELL AS PHARMACOKINETIC PROPERTIES. ACME IS BEST SITED TO PERFORM THIS WORK GIVEN… |
| 2025-03-13 | Inotiv, Inc | $225.6K | TO DEVELOP SMALL SYNTHETIC CHEMICAL MOLECULES AS BROADLY ACTIVE ANTIVIRAL FOR THE TREATMENT OF VIRAL INFECTIONS |
| 2026-06-29 | Curia Global Inc | $207.9K | "CURIA DESCRIPTION OF WORK NON-GMP MANUFACTURE OF APPROXIMATELY3 KILOGRAM OF STF-2586 AND REPROCESSING AND RETESTING OF STF- 2586 TASK 19: NON-GMP BATCH SUBTASK 19A: BATCH PROCEDURE/RECORD REVIEW AND APPROVAL SUBTASK… |
| 2024-05-31 | Curia Global Inc | $206.5K | "CURIA DESCRIPTION OF WORK NON-GMP MANUFACTURE OF APPROXIMATELY3 KILOGRAM OF STF-2586 AND REPROCESSING AND RETESTING OF STF- 2586 TASK 19: NON-GMP BATCH SUBTASK 19A: BATCH PROCEDURE/RECORD REVIEW AND APPROVAL SUBTASK… |
| 2025-07-01 | Acme Bioscience, Inc. | $186.4K | THE MEDICINAL CHEMISTRY FOCUS ON PI4K IS TO IDENTIFY A NOVEL SERIES OF BACK-UP COMPOUNDS THAT ARE DIVERSE WITH OFF-TARGET TOXICITY AS WELL AS PHARMACOKINETIC PROPERTIES. ACME IS BEST SITED TO PERFORM THIS WORK GIVEN… |
| 2024-05-15 | Curia Global Inc | $182.6K | "CURIA DESCRIPTION OF WORK CONDUCT OF A PRELIMINARY SALT SCREEN AND EVALUATION OF PHYSICAL PROPERTIES OF SELECTED CANDIDATE. DETAIL DESCRIPTION OF WORK INVOLVED IS FOUND IN THE CURIA PROPOSAL, SEE SECTIONS 1.1 AND… |
| 2026-06-29 | Inotiv, Inc | $166.6K | TO DEVELOP SMALL SYNTHETIC CHEMICAL MOLECULES AS BROADLY ACTIVE ANTIVIRAL FOR THE TREATMENT OF VIRAL INFECTIONS) ADVANCING A LEAD BROAD SPECTRUM ANTIVIRAL PI-KINASE INHIBITOR |
| 2023-03-10 | Curia Global Inc | $131.1K | CURIA RECENTLY MANUFACTURED NON-GMP STF-2586 AND IS FAMILIAR WITH THE SYNTHESIS PROCESS AND ANALYTICAL METHODS FOR STF-2586. CURIA€„¢S QUOTE IS THE BEST COMBINATION OF EXISTING KNOWLEDGE OF THE STF-2586 PROGRAM… |
| 2024-06-12 | Acme Bioscience, Inc. | $116.6K | THE MEDICINAL CHEMISTRY FOCUS ON PI4K IS TO IDENTIFY A NOVEL SERIES OF BACK-UP COMPOUNDS THAT ARE DIVERSE WITH OFF-TARGET TOXICITY AS WELL AS PHARMACOKINETIC PROPERTIES. ACME IS BEST SITED TO PERFORM THIS WORK GIVEN… |
| 2024-05-31 | Curia Global Inc | $116.0K | "PERFORM ADDITIONAL PROCESS DEVELOPMENT ACTIVITIES TO ESTABLISH A SUITABLE PROCESS PRIOR TO THE 1 KG NON-GMP STF-4326 CAMPAIGN. THIS INCLUDES ONE-MONTH DEVELOPMENT WORK FOR THE SELECTED SALT FORM TO GET THE PROCESS… |
| 2025-09-10 | Aravasc, Inc | $108.8K | TO DEVELOP SMALL SYNTHETIC CHEMICAL MOLECULES AS BROADLY ACTIVE ANTIVIRAL FOR THE TREATMENT OF VIRAL INFECTIONS) ADVANCING A LEAD BROAD SPECTRUM ANTIVIRAL PI-KINASE INHIBITOR T |
| 2023-03-27 | Acme Bioscience, Inc. | $91.0K | SYNTHETIC ORGANIC CHEMISTRY USING CHEMICALS DESIGNED BY STANFORD MEDICINAL CHEMISTS. THE SERVICES TO BE PROVIDED BY ACME UNDER THIS AGREEMENT MAY INCLUDE, BUT NOT BE LIMITED TO: CUSTOM SYNTHESIS, LIBRARY GENERATION,… |
| 2026-07-24 | Inotiv, Inc | $80.2K | TO DEVELOP SMALL SYNTHETIC CHEMICAL MOLECULES AS BROADLY ACTIVE ANTIVIRAL FOR THE TREATMENT OF VIRAL INFECTIONS) ADVANCING A LEAD BROAD SPECTRUM ANTIVIRAL PI-KINASE INHIBITOR |
| 2026-06-03 | Aravasc, Inc | $80.1K | TO DEVELOP SMALL SYNTHETIC CHEMICAL MOLECULES AS BROADLY ACTIVE ANTIVIRAL FOR THE TREATMENT OF VIRAL INFECTIONS) ADVANCING A LEAD BROAD SPECTRUM ANTIVIRAL PI-KINASE INHIBITOR T |
| 2025-05-27 | Inotiv, Inc | $75.4K | TO DEVELOP SMALL SYNTHETIC CHEMICAL MOLECULES AS BROADLY ACTIVE ANTIVIRAL FOR THE TREATMENT OF VIRAL INFECTIONS |
| 2025-03-11 | Inotiv, Inc | $73.2K | TO DEVELOP SMALL SYNTHETIC CHEMICAL MOLECULES AS BROADLY ACTIVE ANTIVIRAL FOR THE TREATMENT OF VIRAL INFECTIONS |
| 2026-05-14 | Inotiv, Inc | $59.0K | TO DEVELOP SMALL SYNTHETIC CHEMICAL MOLECULES AS BROADLY ACTIVE ANTIVIRAL FOR THE TREATMENT OF VIRAL INFECTIONS) ADVANCING A LEAD BROAD SPECTRUM ANTIVIRAL PI-KINASE INHIBITOR |
| 2025-06-24 | Curia Global Inc | $56.6K | "CURIA DESCRIPTION OF WORK NON-GMP MANUFACTURE OF APPROXIMATELY3 KILOGRAM OF STF-2586 AND REPROCESSING AND RETESTING OF STF- 2586 TASK 19: NON-GMP BATCH SUBTASK 19A: BATCH PROCEDURE/RECORD REVIEW AND APPROVAL SUBTASK… |
| 2024-12-19 | Curia Global Inc | $34.5K | "PERFORM ADDITIONAL PROCESS DEVELOPMENT ACTIVITIES TO ESTABLISH A SUITABLE PROCESS PRIOR TO THE 1 KG NON-GMP STF-4326 CAMPAIGN. THIS INCLUDES ONE-MONTH DEVELOPMENT WORK FOR THE SELECTED SALT FORM TO GET THE PROCESS… |
| 2024-05-29 | Curia Global Inc | $32.5K | "CURIA DESCRIPTION OF WORK AND TECHNICAL JUSTIFICATION PREPARATION OF 5 GRAMS OF STF-4326 FREE ACID, 5 GRAMS OF STF-4326 PHOSPHORIC ACID SALT, AND 5 GRAMS OF STF-4326 SODIUM SALT TASK 2: CHEMISTRY… |
| $0 |
| TO DEVELOP SMALL SYNTHETIC CHEMICAL MOLECULES AS BROADLY ACTIVE ANTIVIRAL FOR THE TREATMENT OF VIRAL INFECTIONS |
| 2025-04-28 | P00012 | Change order | $0 | EOI:: IMPLEMENTING THE PRESIDENTS DEPARTMENT OF GOVERNMENT EFFICIENCY COST EFFICIENCY INITIATIVE (MARCH 19, 2025):: EO 14042 - COVID-19. TO DEVELOP SMALL SYNTHETIC CHEMICAL MOLECULES AS BROADLY ACTIVE ANTIVIRAL FOR THE TREATMENT OF VIRAL INFECTIONS |
| 2024-11-25 | P00011 | Administrative change | $0 | EO 14042 - COVID-19. TO DEVELOP SMALL SYNTHETIC CHEMICAL MOLECULES AS BROADLY ACTIVE ANTIVIRAL FOR THE TREATMENT OF VIRAL INFECTIONS. |
| 2024-07-17 | P00010 | Administrative change | $0 | EO 14042 - COVID-19. TO DEVELOP SMALL SYNTHETIC CHEMICAL MOLECULES AS BROADLY ACTIVE ANTIVIRAL FOR THE TREATMENT OF VIRAL INFECTIONS. |
| 2024-05-23 | P00009 | Administrative change | $0 | EO 14042 - COVID-19. TO DEVELOP SMALL SYNTHETIC CHEMICAL MOLECULES AS BROADLY ACTIVE ANTIVIRAL FOR THE TREATMENT OF VIRAL INFECTIONS. |
| 2023-10-17 | P00008 | Administrative change | $0 | EO 14042 - COVID-19. TO DEVELOP SMALL SYNTHETIC CHEMICAL MOLECULES AS BROADLY ACTIVE ANTIVIRAL FOR THE TREATMENT OF VIRAL INFECTIONS. |
| 2023-03-10 | P00007 | Administrative change | $0 | EO 14042 - COVID-19. TO DEVELOP SMALL SYNTHETIC CHEMICAL MOLECULES AS BROADLY ACTIVE ANTIVIRAL FOR THE TREATMENT OF VIRAL INFECTIONS. |
| 2022-12-05 | P00006 | Administrative change | $0 | EO 14042 - COVID-19. TO DEVELOP SMALL SYNTHETIC CHEMICAL MOLECULES AS BROADLY ACTIVE ANTIVIRAL FOR THE TREATMENT OF VIRAL INFECTIONS. |